The Nancy Davis Foundation for Multiple Sclerosis is dedicated to the treatment and ultimate cure of MS. The foundation funds core research conducted by the Center Without Walls program, a selected network of the nation’s top MS research centers.
On May 19, 2012, the foundation held its annual MS Forum and Expo in Los Angeles, which is featured in the video in this program. Listed below are the doctors, researchers, and patients who participated.
If you have progressive relapsing multiple sclerosis (PRMS), your condition will get steadily worse from the very beginning.
But you also will experience distinct relapses, with or without full recovery. Between relapses, the disease continues to gradually worsen.
PRMS is the least common type of multiple sclerosis. It affects about 5% of all people with MS.
Dr. Bakshi is a Professor of Neurology at Brigham and Women's Hospital, Harvard Medical School. He is Director of the Laboratory for Neuroimaging Research at the Partners Multiple Sclerosis Center. He has pursued studies using quantitative neuroimaging funded by the National Institutes of Health, National Science Foundation, and National Multiple Sclerosis Society. He has served as Chair of the Neuroimaging Section and a Fellow of the American Academy of Neurology, President of the American Society of Neuroimaging, and Associate Editor of the journal Neurotherapeutics. He has given more than 200 invited academic lectures and authored more than 190 peer-reviewed articles.
Dennis Bourdette, MD
Dr. Dennis Bourdette is the Director of the MS Center of Oregon at OHSU and the founder of the Jungers Center. Dr. Bourdette’s work has benefited thousands of people suffering from neurological disorders, especially those with multiple sclerosis. He holds a special place in his heart for those with this disease, a passion since his residency in medical school. Recently, he and his colleagues at the MS Center of Oregon have been researching a new therapy for MS that would protect nerve fibers from degeneration. For patients suffering from this debilitating disease, such a therapy would be tremendously beneficial, perhaps delaying or preventing the onset of the paralysis, memory loss, dizziness, fatigue, pain and imbalance associated with MS. Dr. Bourdette is confident that the years ahead will lead to breakthroughs in all areas of brain science. “Over the coming decade, we’re going to see tremendous advances in our ability to treat and prevent a variety of neurological diseases,” he said. “I have more hope than ever for MS patients.”
Peter Calebresi, MD
Peter A. Calabresi, MD is a Professor of Neurology at the Johns Hopkins School of Medicine and Director of the Johns Hopkins Multiple Sclerosis (MS) Center and the Division of Neuroimmunology and Neuroinfectious. As director of the MS Center Diseases at Johns Hopkins, Dr. Calabresi is the principal investigator on several clinical trials. He has designed and directed several clinical trials investigating combination drug therapies in MS and is on the advisory board for three national multi-center clinical trials. Dr. Calabresi also mentors trainees and also oversees translational laboratory research projects within the Division. His specific laboratory research interest lies in understanding how to more specifically target the disease causing effector memory T cells in MS without compromising healthy immune responses. Dr. Calabresi is also the recipient of a new five-year National MS Society collaborative center grant to study mechanisms to promote remyelination in MS.